A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
200
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
Upadacitinib 15mg Dose
DRUG:
Dupilumab 300mg Dose
DRUG:
Upadacitinib 30mg Dose
Sponsor
AbbVie